VigoMed Completes Over RMB 100 Million Series D1 Financing to Advance as a Leader in Laser Medical Technology

VCBeat has learned that Shenzhen Vivolight Medical Device & Technology Co., Ltd. (“Vivolight”), a domestic leader in laser diagnosis and treatment technology innovation, recently completed its Series D1 financing round, raising over RMB 100 million. The round was led by Huajin Capital and Fosun Health Capital, with participation from Kaihe Capital and existing investors HongShan and CASSTAR. The funds will be used for the development and clinical application of laser therapy products in the fields of neurosurgery, peripheral vascular disease, and ophthalmology.

Vivolight, established in 2012, is a pioneer and innovative leader in the field of laser medicine in China. Over the past decade since its founding, the company has remained committed to the development of foundational core technologies and independent innovation, building three major underlying core technology platforms: ultrafast laser, fiber optic catheters, and image processing. It currently holds more than 140 intellectual property rights with independent ownership. Many of Vivolight’s products have achieved industry firsts: it developed and manufactured China’s first cardiovascular OCT imaging system for export, the world’s first mobile cardiovascular OCT imaging system, and the world’s first multimodal OCT imaging system; it established the world’s first fully automated production line for OCT fiber optic probes; and it has built the leading brand in the infrared vascular imaging segment, ranking first in China and second globally.

According to data from the U.S. research firm Fortune Business Insights, the global market size for medical laser equipment was approximately USD 4.15 billion in 2021, with a projected compound annual growth rate (CAGR) of 16.8% over the next eight years. Frost & Sullivan estimates that China’s medical laser market will exceed RMB 30 billion in 2022, indicating substantial growth potential and establishing it as an emerging sector that can no longer be overlooked. Currently, the application of lasers in the medical field is becoming increasingly widespread, spanning ophthalmology, surgery, cardiology, internal medicine, gynecology, otolaryngology, dermatology, and other specialties, all of which have become established areas for laser-based medical devices.

Vivolight’s newly launched P80 Cardiovascular OCT System is currently the most technologically advanced and meticulously engineered intravascular OCT imaging system, boasting 13 unique and leading indicators compared to imported products. Meanwhile, Vivolight is the domestic brand with the most comprehensive OCT product portfolio in the industry. The company has also achieved phased progress in other pan-vascular, urological, and ophthalmic diagnostic and therapeutic areas, such as carotid artery OCT and cold laser ablation, which will be introduced into clinical use as soon as possible. Furthermore, Vivolight is fully accelerating the localization of core components to ensure supply chain security while reducing costs.

Since 2021, Vivolight’s OCT product sales have grown rapidly, capturing a leading share among domestically produced OCT systems. In many niche segments of laser medicine, no monopolistic giants have yet emerged. As a leading Chinese laser medical technology company, Vivolight will leverage its substantial technological and product advantages to drive innovation in laser applications across multiple clinical areas.

On September 3, the National Healthcare Security Administration officially issued a document stating that innovative medical devices will not be subject to volume-based procurement, explicitly aiming to create market space for innovative products.

Recently, with the implementation of review guidelines for medical device companies on the STAR Market and the successful listings of MicroPort EP and United Imaging Healthcare, Vivolight is poised to seize new opportunities for its own STAR Market debut.